MGA’s Latest Work Examining Digital Health Tools
MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.”
New MGA Analysis of the Adalimumab Biosimilars Market in the United States
The Biosimilars Council released the following statement in response to the new MGA report authored by Alex Brill and Christy Robinson.
New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets
MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.”
New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit
A new MGA white paper from CEO Alex Brill and Principal Christy Robinson shows a positive outlook for biosimilar coverage in the commercial medical benefit.
Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology
MGA releases an updated report, “Biosimilar Market Opportunities in Ophthalmology.”
MGA Releases Economic Impact Report for Multinational Pharmaceutical Company
In a newly released report, MGA highlights the broad economic impact of Otsuka Pharmaceutical in the U.S. operations.
- PBM Concerns Induce Surprising Bipartisanship
- MGA’s Latest Work Examining Digital Health Tools
- ‘The Price of Business’: Discussing the Debt Crisis
- A More Affordable Future Through Competition
- A Drug with Two Prices
- ‘The Price of Business’: Discussing the Future of Working at Home
- Health Care Workforce Shortages: An Updated Look
- New MGA Analysis of the Adalimumab Biosimilars Market in the United States
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing the Recent Tax Policy Proposal
- Bipartisan Senate Bill Aims to Curb Drug Patent Abuse
